Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma

Dipeng Ou; Hao Yang; Dong Hua; Shuai Xiao; Lianyue Yang

doi:10.18632/oncotarget.3954

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma

Dipeng Ou _, Hao Yang, Dong Hua, Shuai Xiao and Lianyue Yang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:17379-17390. https://doi.org/10.18632/oncotarget.3954

Metrics: PDF 2740 views | HTML 2851 views | ?

Abstract

Dipeng Ou1,*, Hao Yang1,*, Dong Hua1, Shuai Xiao1 and Lianyue Yang2,3

1 Department of Geratic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

2 Department of Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

3 Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan, China

* These authors have contributed equally to this work

Correspondence to:

Dipeng Ou, email:

Keywords: TMEM100; HCC; metastasis; proliferation; prognosis

Received: January 10, 2015 Accepted: April 08, 2015 Published: April 29, 2015

Abstract

Transmembrane protein 100 (TMEM100) was activated by ALK1/TGF-β signaling. We found that TMEM100 was decreased in hepatocellular carcinoma (HCC) tissues and in highly metastatic cell lines. Overexpressed of TMEM100 inhibited invasion, migration and proliferation. Low levels of TMEM100 were associated with cirrhosis, tumor size, Tumor nodule number, TNM stage, BCLC stage, Edmondson-Steiner Stage and vein invasion. Furthermore, TMEM100 was an independent risk factor for overall survival (P = 0.03) and disease-free survival (P = 0.019). The current findings suggest that TMEM100 functions as a tumor suppressor in HCC metastasis and proliferation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3954

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma

Abstract